Alector Q1 net loss $45.9M, cash $669.3M; on track for latozinemab INFRONT-3 regulatory engagement in mid-2023

Alector, Inc.

2023-Q1 EPS reported -$0.55 revenue$16,549,000

Revenue $16.5M (down $8M YoY); net loss $45.9M ($0.55/share) vs $44.6M ($0.54/share) in Q1 2022.
Cash, equivalents and investments $669.3M; management expects runway through 2025.
On track to discuss INFRONT-3 (latozinemab in FTD-GRN) with regulators mid-2023; data readout early 2025.
Received $17.8M milestone from AbbVie for AL002 LTE enrollment; INVOKE-2 top-line data expected Q4 2024.
2023 guidance: collaboration revenue $15-25M, R&D expense $225-245M, G&A $60-70M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Alector, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 4, 2023, Alector, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Alector, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-017859

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.